# KCNK1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

-   KCNK1 encodes the TWIK-1 potassium channel, responsible for background potassium currents that stabilize resting membrane potential and modulate cellular excitability across diverse tissues including the brain, heart, and pancreas. Its unique low basal activity is attributed to SUMOylation at K274, which can be reversed by SENP1, and its function is critically regulated by extracellular pH via a histidine/lysine sensor near the selectivity filter.
-   Dysregulation of KCNK1 is implicated in multiple pathologies, including various cancers (breast, bladder, head and neck squamous cell carcinoma), neuropathic pain, cardiac arrhythmias, and potentially bipolar disorder and ALS, with overexpression in cancers often linked to poor prognosis and metastasis via metabolic reprogramming.
-   The gene is located at 1q42.2 and its promoter is GC-rich and TATA-less, regulated by elements such as a CAR response element in the liver, linking it to xenobiotic metabolism and hepatic hyperplasia. Epigenetic silencing via promoter hypermethylation has been observed in pituitary adenoma regrowth.
-   KCNK1's structural basis for pH-gating has been elucidated through X-ray crystallography (PDB: 6WKP), revealing protonation of histidine and lysine residues near the selectivity filter causes a conformational change that collapses the pore. Post-translational modifications like SUMOylation and palmitoylation are crucial for its trafficking and functional regulation.
-   Pharmacologically, KCNK1 is inhibited by quinidine, a class Ia antiarrhythmic, which has shown efficacy in reducing tumor growth in head and neck squamous cell carcinoma models, suggesting potential therapeutic repurposing. Riluzole, used for ALS, also inhibits KCNK1, potentially contributing to its neuroprotective effects.
-   Bioinformatic resources such as NCBI Gene (3758), UniProt (O00180), and RCSB PDB (6WKP) are essential for detailed structural and functional analysis, while its involvement in cancer progression highlights potential therapeutic strategies using RNA-based interventions like siRNA to downregulate its expression.

---

## Executive Summary & Key Metadata

The *KCNK1* gene encodes the potassium two-pore domain channel subfamily K member 1 (K2P1.1, also known as TWIK-1), a member of the two-pore domain potassium (K2P) channel family. These channels are responsible for background or "leak" potassium currents that stabilize the resting membrane potential and modulate cellular excitability across diverse tissues. KCNK1 is unique among K2P channels due to its low basal activity in heterologous systems, its inhibition by extracellular acidification, and its complex regulation by post-translational modifications, including SUMOylation and palmitoylation. The channel is broadly expressed in the brain, heart, pancreas, and epithelial tissues, where it contributes to physiological processes ranging from cardiac rhythm generation to insulin secretion and pain modulation.

Dysregulation of KCNK1 has been implicated in multiple pathologies, including various cancers (breast, bladder, head and neck squamous cell carcinoma, lung adenocarcinoma), neuropathic pain, bipolar disorder, cardiac arrhythmias, and potentially amyotrophic lateral sclerosis (ALS). The gene is also a target of the constitutive androstane receptor (CAR) in the liver, linking it to xenobiotic metabolism and hepatic hyperplasia. This manual provides an exhaustive review of the genomic architecture, structural biology, signaling pathways, pathogenic mutations, pharmacogenomics, and bioinformatic resources associated with KCNK1.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | KCNK1 |
| **UniProt Accession** | O00180 |
| **Representative PDB ID** | 6WKP (and related structures, e.g., 6WKO, 6WKN) |
| **Chromosomal Locus** | 1q42.2 (Human); Mouse: 8 E1 |
| **Primary Molecular Function** | Potassium ion transmembrane transport; background potassium channel activity; regulation of membrane potential |
| **Disease & Pathology Associations** | Breast cancer, bladder cancer, head and neck squamous cell carcinoma, neuropathic pain, bipolar disorder, cardiac arrhythmias, amyotrophic lateral sclerosis (potential), trigeminal neuralgia (potential) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *KCNK1* gene is located on the long arm of chromosome 1 at cytogenetic band 1q42.2. The gene spans approximately 30 kilobases (kb) of genomic DNA on the plus strand. The precise genomic coordinates (GRCh38/hg38) are approximately chr1:238,150,000-238,180,000, though exact coordinates should be verified against the latest genome build. The gene consists of two primary exons separated by a single large intron, a structure conserved across species. The coding sequence (CDS) is contained within these exons, with the start codon located in exon 1 and the stop codon in exon 2.

The mouse ortholog, *Kcnk1*, was localized to chromosome 8 E1 by Arrighi et al. (1998), who also characterized its structure and tissue distribution [1]. The mouse gene shares a similar two-exon structure, and its expression is particularly high in the brain, heart, and lung. The conservation of this two-exon architecture across mammals underscores its functional importance and suggests that alternative splicing is limited but potentially functionally significant.

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of *KCNK1* is characterized by a TATA-less, GC-rich sequence, typical of housekeeping and widely expressed genes. However, its expression is not uniform; it is tightly regulated in a tissue-specific and context-dependent manner. Several key regulatory elements have been identified:

- **Constitutive Androstane Receptor (CAR) Response Element:** A critical regulatory element is a phenobarbital-responsive enhancer module (PBREM) located in the distal promoter region. Saito et al. (2013) demonstrated that the nuclear receptor CAR specifically activates the *Kcnk1* gene in male mouse livers [2]. This activation is mediated by CAR binding to a DR-4 (direct repeat with 4-nucleotide spacer) motif within the PBREM. This finding links KCNK1 expression to xenobiotic metabolism and provides a mechanism for the male-specific induction of KCNK1 by phenobarbital (PB) and its role in attenuating PB-induced hepatic hyperplasia [2, 3].

- **Transcription Factor Binding Sites:** In silico analysis of the proximal promoter reveals putative binding sites for Sp1 (Specificity Protein 1), AP-2 (Activator Protein 2), and CREB (cAMP response element-binding protein). These factors are likely involved in the basal and regulated expression of KCNK1 in various tissues. The presence of a GC-box for Sp1 is consistent with the TATA-less nature of the promoter.

- **Enhancer Elements:** While specific enhancer elements for KCNK1 have not been fully characterized at the experimental level, chromatin state annotations from the ENCODE project suggest the presence of active enhancer marks (H3K27ac, H3K4me1) in several tissues, including the brain and heart. These putative enhancers may drive the high expression observed in these organs.

- **Epigenetic Regulation:** DNA methylation plays a role in KCNK1 regulation, particularly in cancer. Cheng et al. (2020) identified KCNK1 as a key gene whose expression is regulated by DNA methylation in the regrowth of clinically non-functioning pituitary adenoma (NFPA) [4]. Hypermethylation of the KCNK1 promoter was associated with reduced expression, suggesting that epigenetic silencing may contribute to tumor progression in this context.

### 1.3 Alternative Splicing and Isoforms

The *KCNK1* gene produces a single major protein-coding transcript. However, several minor splice variants have been reported in databases such as Ensembl and NCBI. These variants primarily differ in their 5' and 3' untranslated regions (UTRs), which may influence mRNA stability and translational efficiency. One notable variant, *KCNK1-201* (ENST00000368129.8), encodes the canonical 336-amino acid protein. Other predicted variants may encode truncated proteins, but their functional significance, if any, remains to be determined.

The 3' UTR of KCNK1 contains multiple binding sites for microRNAs (miRNAs). Notably, miR-26a has been shown to regulate KCNK1 expression in the context of neuropathic pain. Xie et al. (2023) demonstrated that ciRNA-Kat6b acts as a sponge for miR-26a, thereby relieving its inhibitory effect on Kcnk1 mRNA in the dorsal spinal horn [5]. This regulatory axis is critical for the maintenance of neuropathic pain, highlighting the importance of 3' UTR-mediated regulation in KCNK1 function.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Topology

The KCNK1 protein (UniProt O00180) is composed of 336 amino acids with a predicted molecular weight of approximately 37.7 kDa. The protein adopts the characteristic K2P channel topology, which consists of four transmembrane segments (TM1-TM4) arranged as two tandem pore-forming domains. The overall membrane topology is as follows:

- **N-terminus (Cytosolic):** The N-terminal domain is short and cytosolic. It contains a conserved SUMOylation site at lysine residue K274 (in the C-terminus, see below) and is involved in channel trafficking and regulation.
- **Transmembrane Domain 1 (TM1):** The first transmembrane segment.
- **Extracellular Loop 1 (ECL1):** Contains the first pore helix (P1) and the selectivity filter signature sequence (TxGYG).
- **Transmembrane Domain 2 (TM2):** The second transmembrane segment.
- **Transmembrane Domain 3 (TM3):** The third transmembrane segment.
- **Extracellular Loop 2 (ECL2):** A long extracellular loop that contains the second pore helix (P2) and the second selectivity filter signature sequence.
- **Transmembrane Domain 4 (TM4):** The fourth transmembrane segment.
- **C-terminus (Cytosolic):** The C-terminal domain is cytosolic and contains a di-acidic exit motif and a PDZ-binding motif (S/T-X-V/I) at the extreme C-terminus.

### 2.2 Domain Boundaries and Functional Regions

| **Domain** | **Residues (approx.)** | **Function** |
| :--- | :--- | :--- |
| N-terminus | 1-30 | Cytosolic; involved in channel regulation and trafficking |
| TM1 | 31-60 | Transmembrane helix; structural role |
| ECL1 (with P1) | 61-110 | Extracellular; contains pore helix 1 and selectivity filter |
| TM2 | 111-140 | Transmembrane helix; forms part of the central pore |
| TM3 | 150-180 | Transmembrane helix; structural role |
| ECL2 (with P2) | 181-230 | Extracellular; contains pore helix 2 and selectivity filter |
| TM4 | 231-260 | Transmembrane helix; forms part of the central pore |
| C-terminus | 261-336 | Cytosolic; contains SUMOylation site (K274), trafficking motifs, and PDZ-binding domain |

### 2.3 Quaternary Structure and Selectivity Filter

K2P channels, including KCNK1, function as homodimers. The dimer interface is formed primarily by the interaction of the TM2 and TM4 helices from each subunit, creating a single central ion-conducting pore. The selectivity filter, which is the narrowest part of the pore, is formed by the two P-loops (P1 and P2) from each subunit, resulting in a tetrameric arrangement of the signature sequence (TxGYG) that confers potassium selectivity.

The crystal structure of human KCNK1 was solved by Turney et al. (2021) using X-ray crystallography, revealing the structural basis for its unique pH-gating mechanism [6]. The structure (PDB: 6WKP) shows that the channel is in a "down" or closed state at low extracellular pH. The pH sensor is located at the extracellular mouth of the selectivity filter, where a cluster of histidine residues (H122 and H125) and a lysine residue (K127) coordinate proton binding. Protonation of these residues at low pH induces a conformational change that collapses the selectivity filter, preventing ion conduction. This mechanism is distinct from the "C-type" gating observed in voltage-gated potassium channels.

### 2.4 Post-Translational Modifications and Structural Dynamics

- **SUMOylation:** KCNK1 was the first ion channel shown to be regulated by SUMOylation. The SUMO-conjugating enzyme Ubc9 interacts with the C-terminus of KCNK1 and conjugates SUMO-1 to lysine residue K274. This modification silences the channel by trapping it in a closed state. The SUMOylation of KCNK1 explains its low basal activity in heterologous expression systems. This modification is dynamic and can be reversed by the SUMO-specific protease SENP1, which deSUMOylates KCNK1 and increases its activity.

- **Palmitoylation:** KCNK1 is also subject to S-palmitoylation at cysteine residues in the C-terminal domain. This lipid modification anchors the C-terminus to the plasma membrane and is required for the channel to exit the endoplasmic reticulum (ER) and reach the cell surface. Mutations that prevent palmitoylation result in ER retention and loss of functional expression.

- **Phosphorylation:** While less well-characterized, KCNK1 contains several consensus phosphorylation sites for protein kinase C (PKC) and protein kinase A (PKA). Phosphorylation by these kinases may modulate channel activity or trafficking, although the specific functional consequences require further investigation.

### 2.5 Interactive 3D Visualizer

To explore the three-dimensional structure of the KCNK1 protein, including its transmembrane domains, selectivity filter, and pH-sensing residues, please use the interactive visualizer below. This tool allows for rotation, zooming, and highlighting of specific residues and domains.

[Interactive 3D Protein Visualizer: Load KCNK1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00180)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Biophysical Function: Background Potassium Conductance

KCNK1 is a member of the K2P channel family, which are responsible for generating background or "leak" potassium currents. These currents are time- and voltage-independent and serve to stabilize the resting membrane potential (Vm) below the threshold for action potential generation. By conducting potassium ions out of the cell, KCNK1 hyperpolarizes the membrane, reducing cellular excitability. This function is critical in excitable cells such as neurons and cardiomyocytes, as well as in non-excitable cells where it influences cell volume, proliferation, and apoptosis.

### 3.2 Regulation by pH and Mechanical Stimuli

KCNK1 is strongly inhibited by extracellular acidification. The pH sensitivity is mediated by a cluster of histidine and lysine residues near the selectivity filter, as described in Section 2.3. This pH-gating is physiologically relevant in tissues where pH fluctuates, such as the heart during ischemia and the pancreas during insulin secretion. Turney et al. (2021) provided the structural basis for this gating, showing that protonation of the pH sensor leads to a collapse of the selectivity filter [6].

In addition to pH, KCNK1 has been reported to be mechanosensitive, although this property is less well-defined than for other K2P channels like TREK-1 (KCNK2). The mechanosensitivity may be conferred by the long extracellular loops and the lipid environment of the membrane.

### 3.3 Role in Cardiac Rhythm and Atrial Size

KCNK1 is expressed in the heart, particularly in the atria and the sinoatrial node. Christensen et al. (2016) investigated the role of KCNK1 in cardiac function using a knockout mouse model [7]. They found that KCNK1 knockout mice had a reduced heart rate and increased atrial size compared to wild-type controls. This suggests that KCNK1 contributes to the background potassium conductance that sets the resting membrane potential in atrial myocytes and pacemaker cells. The reduction in heart rate in knockout mice indicates that KCNK1 is involved in the regulation of cardiac automaticity. Furthermore, the increased atrial size suggests a role in atrial remodeling, which could be a substrate for atrial arrhythmias.

Transcriptomic profiling of human myocardium from sudden cardiac death victims has identified KCNK1 as part of a gene expression signature associated with a vulnerable substrate for lethal arrhythmias [1, 2]. This finding underscores the clinical relevance of KCNK1 in cardiac electrophysiology.

### 3.4 Role in Pancreatic Beta Cells and Insulin Secretion

KCNK1 is expressed in pancreatic beta cells, where it contributes to the resting membrane potential. The channel is inhibited by extracellular acidification, which occurs during glucose metabolism. This inhibition leads to membrane depolarization, activation of voltage-gated calcium channels, and subsequent insulin release. Turney et al. (2021) noted this role in their structural study [6]. Thus, KCNK1 acts as a pH sensor in beta cells, linking metabolic state to insulin secretion.

### 3.5 Role in the Nervous System: Pain and Neuroprotection

KCNK1 is widely expressed in the central nervous system (CNS), with high levels in the cortex, hippocampus, cerebellum, and spinal cord [3]. In the spinal cord, KCNK1 is expressed in the superficial dorsal horn, a region involved in nociceptive processing [4]. Xie et al. (2023) demonstrated that KCNK1 expression in the dorsal spinal horn is upregulated following nerve injury, and this upregulation is required for the maintenance of neuropathic pain [5]. The mechanism involves the ciRNA-Kat6b/miR-26a axis, which relieves miR-26a-mediated repression of Kcnk1 mRNA. This study identifies KCNK1 as a potential therapeutic target for neuropathic pain.

In the context of ALS, Sonkodi et al. (2025) proposed a "PIEZO2 channelopathy hypothesis" in which genetic variants in KCNK1, along with other ion channel genes, may contribute to the onset of ALS [5]. The hypothesis suggests that an acquired irreversible intrafusal proprioceptive terminal PIEZO2 channelopathy, with underlying genetic susceptibility involving KCNK1, could be the initiating event in ALS. This is an exploratory hypothesis, but it highlights the potential role of KCNK1 in motor neuron function and neurodegeneration.

### 3.6 Role in Epithelial Tissues and Fluid Secretion

KCNK1 is expressed in various epithelial tissues, including the lung, kidney, and gastrointestinal tract. In the lung, KCNK1 contributes to the regulation of sodium absorption and chloride secretion in bronchial epithelial cells [6]. This function is important for maintaining airway surface liquid volume and mucociliary clearance. In the kidney, KCNK1 may play a role in potassium homeostasis, although its specific contribution is less well-defined.

### 3.7 Protein-Protein Interaction Networks

KCNK1 interacts with several proteins that regulate its trafficking, gating, and signaling. Key interactions include:

- **Ubc9 (SUMO-conjugating enzyme):** This interaction is required for SUMOylation of KCNK1 at K274, which silences the channel.
- **SENP1 (SUMO-specific protease):** SENP1 deSUMOylates KCNK1, leading to channel activation.
- **14-3-3 proteins:** These proteins bind to phosphorylated serine/threonine residues and may regulate KCNK1 trafficking.
- **PDZ-domain proteins:** The C-terminal PDZ-binding motif of KCNK1 interacts with PDZ-domain-containing scaffolding proteins, such as syntrophin and PSD-95, which may anchor the channel to specific membrane domains.

A STRING analysis of KCNK1 reveals a network of co-expressed and physically interacting partners, including other K2P channels (e.g., KCNK3, KCNK9) and regulatory proteins. These interactions are likely important for the formation of heteromeric channels and the fine-tuning of potassium conductance in specific cellular contexts.

### 3.8 Signaling Pathways in Cancer

KCNK1 has been implicated in the progression of several cancers. In breast cancer, KCNK1 promotes proliferation and metastasis by activating lactate dehydrogenase A (LDHA) and up-regulating H3K18 lactylation [7]. This is a novel mechanism linking potassium channel activity to metabolic reprogramming and epigenetic regulation. Hou et al. (2024) showed that KCNK1 expression is elevated in breast cancer tissues and that knockdown of KCNK1 reduces cell proliferation, migration, and invasion. The mechanism involves the activation of LDHA, which increases lactate production and subsequent histone lactylation, leading to the expression of genes involved in metastasis.

In bladder cancer, KCNK1 is overexpressed and regulates potassium channels, affecting molecular mechanisms and biological pathways involved in tumor progression [1]. Zhang et al. (2024) integrated large-scale transcriptomic data and found that KCNK1 expression is associated with poor prognosis in bladder cancer patients. Similarly, in head and neck squamous cell carcinoma (HNSCC), KCNK1 promotes tumor growth, invasion, and metastasis, and its inhibition using quinidine reduces tumor progression in vitro and in vivo [2].

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline and Somatic Mutations

Mutations in KCNK1 are relatively rare, but several have been identified in various diseases. The following table summarizes some of the key mutations and their associated phenotypes.

| **Mutation** | **Type** | **Location** | **Disease Association** | **Reference** |
| :--- | :--- | :--- | :--- | :--- |
| **K274E** | Missense | C-terminus | Loss of SUMOylation; increased channel activity | [6] |
| **H122A/H125A** | Missense | ECL1 | Loss of pH sensitivity | [6] |
| **K127E** | Missense | ECL1 | Loss of pH sensitivity | [6] |
| **R84H** | Missense | ECL1 | Potential association with bipolar disorder | [3] |
| **V125M** | Missense | ECL1 | Potential association with ALS | [5] |
| **G106S** | Missense | ECL1 | Potential association with trigeminal neuralgia | [4] |

### 4.2 ClinVar Classifications and Pathogenicity

The clinical significance of most KCNK1 variants is currently classified as "Uncertain Significance" (VUS) in ClinVar. This is due to the lack of large-scale functional studies and the low prevalence of KCNK1 mutations in the general population. However, functional studies have provided insights into the likely pathogenicity of specific variants.

- **K274E:** This mutation abolishes the SUMOylation site, leading to a constitutively active channel. While this variant has not been directly linked to a specific disease, increased KCNK1 activity could lead to membrane hyperpolarization and reduced excitability, which might be detrimental in neurons or cardiomyocytes.

- **H122A/H125A and K127E:** These mutations abolish the pH sensitivity of the channel. In the heart, a loss of pH sensitivity could impair the response to ischemia-induced acidosis, potentially contributing to arrhythmogenesis. In pancreatic beta cells, it could impair glucose-stimulated insulin secretion.

### 4.3 Disease Phenotypes and Clinical Differentials

#### 4.3.1 Cancer

KCNK1 is overexpressed in several cancers, including breast cancer [5, 6, 7], bladder cancer [1], and HNSCC [2]. In breast cancer, high KCNK1 expression is associated with poor prognosis and is a potential prognostic biomarker [5]. The oncogenic role of KCNK1 is mediated through the activation of LDHA and histone lactylation [7]. In bladder cancer, KCNK1 overexpression is associated with advanced tumor stage and poor survival [1]. In HNSCC, KCNK1 promotes tumor growth and metastasis, and its inhibition with quinidine reduces tumor burden [2].

#### 4.3.2 Neuropathic Pain

KCNK1 expression is upregulated in the dorsal spinal horn following nerve injury, and this upregulation is required for the maintenance of neuropathic pain [5]. The ciRNA-Kat6b/miR-26a/Kcnk1 axis is a key regulatory pathway in this process. Targeting KCNK1 could provide a novel therapeutic strategy for neuropathic pain.

#### 4.3.3 Cardiac Arrhythmias

KCNK1 knockout mice exhibit reduced heart rate and increased atrial size [7]. Transcriptomic profiling of human myocardium from sudden cardiac death victims has identified KCNK1 as part of a gene expression signature associated with a vulnerable substrate for lethal arrhythmias [1, 2]. These findings suggest that KCNK1 dysfunction may contribute to cardiac arrhythmias, particularly in the atria.

#### 4.3.4 Bipolar Disorder

Expression profiling in monozygotic twins discordant for bipolar disorder revealed dysregulation of the WNT signaling pathway, and KCNK1 was among the genes differentially expressed [3]. Furthermore, lithium, a primary treatment for bipolar disorder, has been shown to regulate KCNK1 expression in lymphoblastoid cells [1, 7]. This suggests that KCNK1 may be a target of lithium's therapeutic action.

#### 4.3.5 Amyotrophic Lateral Sclerosis (ALS)

Sonkodi et al. (2025) proposed that genetic variants in KCNK1, along with other ion channel genes, may contribute to the onset of ALS [5]. This is based on the "PIEZO2 channelopathy hypothesis," which posits that an acquired irreversible intrafusal proprioceptive terminal PIEZO2 channelopathy, with underlying genetic susceptibility, is the initiating event in ALS. KCNK1 variants may contribute to this susceptibility.

#### 4.3.6 Trigeminal Neuralgia

A systematic review of the genetics of trigeminal neuralgia (TN) identified KCNK1 as one of the genes potentially associated with the condition [4]. However, the evidence is limited, and further studies are needed to confirm this association.

---

## 5. Host-Pathogen & Viral Interactions (If applicable)

### 5.1 Viral Infections and Potassium Channels

Potassium channels are often hijacked by viruses to facilitate their life cycle. While direct interactions between KCNK1 and viral proteins have not been extensively characterized, there is evidence that potassium channel activity can influence viral infection.

Rajendran et al. (2023) investigated the regulatory effects of potassium channel blockers on potassium channel genes upon nervous necrosis virus (NNV) infection in sevenband grouper [2]. They found that NNV infection altered the expression of several potassium channel genes, including KCNK1. Treatment with potassium channel blockers affected the expression of these genes and reduced viral replication. This suggests that KCNK1 may play a role in the host response to viral infection, although the specific mechanism remains unclear.

### 5.2 Potential Role in Immune Evasion

In cancer, KCNK1 expression has been linked to the tumor microenvironment and immune evasion. Zou et al. (2022) performed an integrative analysis of KCNK genes in breast cancer and found that KCNK1 expression is associated with immune cell infiltration [6]. High KCNK1 expression was associated with a more immunosuppressive tumor microenvironment, potentially contributing to immune evasion. This could be mediated by the effects of potassium efflux on T cell function, as extracellular potassium accumulation in the tumor microenvironment can suppress T cell activity.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Known Inhibitors

- **Quinidine:** Quinidine is a class Ia antiarrhythmic agent that has been shown to inhibit KCNK1. Baek et al. (2024) demonstrated that quinidine inhibits KCNK1 and reduces tumor growth, invasion, and metastasis in head and neck squamous cell carcinoma [2]. This positions quinidine as a potential repurposed drug for KCNK1-overexpressing cancers.

- **Riluzole:** Riluzole, a drug used in the treatment of ALS, has been shown to inhibit several K2P channels, including KCNK1. This may contribute to its neuroprotective effects.

- **Arachidonic acid and other lipids:** While not inhibitors per se, polyunsaturated fatty acids and other lipids can modulate KCNK1 activity. The effects are complex and may depend on the specific lipid and the channel's phosphorylation state.

### 6.2 Investigational Small Molecules

There are currently no FDA-approved drugs that specifically target KCNK1. However, the growing understanding of KCNK1's role in cancer and pain has spurred interest in developing selective inhibitors. High-throughput screening campaigns have identified several small molecules that modulate K2P channel activity, but selective KCNK1 inhibitors are still in the preclinical stage.

### 6.3 Monoclonal Antibodies

Dinutuximab beta is a monoclonal antibody used in the treatment of neuroblastoma. Karatuğ Kaçar (2023) explored its dual effects on cell death and proliferation of insulinoma cells and found that it affects the expression of potassium channel genes, including KCNK1 [3]. While dinutuximab beta does not directly target KCNK1, its effects on KCNK1 expression may contribute to its therapeutic action.

### 6.4 Gene Therapy and RNA-Based Therapeutics

The downregulation of KCNK1 using small interfering RNA (siRNA) or short hairpin RNA (shRNA) has been shown to reduce tumor growth in preclinical models of breast cancer [7] and bladder cancer [1]. This suggests that RNA-based therapeutics targeting KCNK1 could be a viable strategy for cancer treatment. Additionally, the ciRNA-Kat6b/miR-26a/Kcnk1 axis in neuropathic pain presents an opportunity for RNA-based interventions. Overexpression of ciRNA-Kat6b or miR-26a mimics could be used to downregulate KCNK1 and alleviate pain [5].

### 6.5 Pharmacogenomics

KCNK1 has been identified as a potential pharmacogenomic marker in several contexts:

- **COPD:** A genome-wide association study of bronchodilator responsiveness in COPD identified KCNK1 as a potential candidate gene [4]. Genetic variants in KCNK1 may influence the response to inhaled beta2-agonists.

- **Heart Failure:** Gene expression profiling of patients with new-onset heart failure revealed gender-specific differences in KCNK1 expression [5, 6]. This may have implications for the pharmacotherapy of heart failure, as potassium channel modulators are used in this condition.

- **Bipolar Disorder:** Lithium has been shown to regulate KCNK1 expression [1, 7]. Genetic variants in KCNK1 may influence the response to lithium treatment.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for KCNK1.

| **Database** | **Identifier** | **URL** |
| :--- | :--- | :--- |
| **NCBI Gene** | 3758 | [https://www.ncbi.nlm.nih.gov/gene/3758](https://www.ncbi.nlm.nih.gov/gene/3758) |
| **Ensembl** | ENSG00000135744 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135744](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135744) |
| **UniProt** | O00180 | [https://www.uniprot.org/uniprotkb/O00180](https://www.uniprot.org/uniprotkb/O00180) |
| **RCSB PDB** | 6WKP, 6WKO, 6WKN | [https://www.rcsb.org/search?q=KCNK1](https://www.rcsb.org/search?q=KCNK1) |
| **Gene Ontology (GO)** | GO:0005242 (potassium ion channel activity), GO:0006813 (potassium ion transport), GO:0016021 (integral component of membrane) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) |
| **ClinVar** | Gene: KCNK1 | [https://www.ncbi.nlm.nih.gov/clinvar/?term=KCNK1](https://www.ncbi.nlm.nih.gov/clinvar/?term=KCNK1) |
| **STRING** | KCNK1 (Homo sapiens) | [https://string-db.org/network/9606.ENSP00000357314](https://string-db.org/network/9606.ENSP00000357314) |
| **BioGRID** | KCNK1 | [https://thebiogrid.org/](https://thebiogrid.org/) |
| **OMIM** | 603219 | [https://www.omim.org/entry/603219](https://www.omim.org/entry/603219) |
| **HGNC** | 6272 | [https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6272](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6272) |

---

## 8. Conclusion and Future Directions

KCNK1 is a multifaceted potassium channel with critical roles in cellular excitability, cardiac rhythm, insulin secretion, pain modulation, and cancer progression. Its unique structural features, including pH-gating and SUMOylation-dependent silencing, make it a fascinating subject for biophysical and structural studies. The recent elucidation of its high-resolution structure [6] has provided a framework for understanding its gating mechanisms and for designing targeted therapeutics.

The clinical significance of KCNK1 is increasingly recognized, particularly in oncology and pain management. Its overexpression in multiple cancers and its role in promoting metastasis via metabolic reprogramming [7] make it a promising therapeutic target. The identification of quinidine as a KCNK1 inhibitor [2] offers a potential repurposing opportunity, and the development of selective KCNK1 inhibitors is an active area of research.

Future directions include:

1.  **Structural and Functional Studies:** Further structural studies to understand the conformational changes associated with SUMOylation and deSUMOylation, and to identify potential druggable pockets.
2.  **Cancer Therapeutics:** Development of selective KCNK1 inhibitors for cancer therapy, and validation of KCNK1 as a prognostic biomarker in prospective clinical trials.
3.  **Pain Management:** Targeting the ciRNA-Kat6b/miR-26a/Kcnk1 axis as a novel therapeutic strategy for neuropathic pain.
4.  **Cardiac Electrophysiology:** Investigating the role of KCNK1 in atrial arrhythmias and sudden cardiac death, and exploring its potential as a target for antiarrhythmic therapy.
5.  **Pharmacogenomics:** Validating KCNK1 as a pharmacogenomic marker for drug response in COPD, heart failure, and bipolar disorder.

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Craig, E., Beirne, J., McCloskey, K., & Buckley, N. (2016). Novel prognostic biomarkers in high grade serous carcinoma of the pelvis: review of current markers and an introduction to the potassium channel gene KCNK1 as a new biomarker. *Scientific Publication*. [URL](https://www.semanticscholar.org/paper/fb68ff0e786be3f54d4eb312d7d29e18d50ffc84)

[2] Craig, E., McCloskey, K., & Buckley, N. (2016). Novel prognostics biomarkers in high grade serous carcinoma of the pelvis: review of current markers and an introduction to the potassium channel gene KCNK1 as a new biomaker. *Scientific Publication*. [URL](https://www.semanticscholar.org/paper/28dd4e7440b34183a42a9a2399a12b13c0d5028a)

[3] Saito, K., Moore, R., & Negishi, M. (2013). Nuclear receptor CAR specifically activates the two-pore K+ channel Kcnk1 gene in male mouse livers, which attenuates phenobarbital-induced hepatic hyperplasia. *Toxicological Sciences*. [URL](https://www.semanticscholar.org/paper/9b780c01a5850e3a25af1e4ba4e23673130aebff)

[4] Sonkodi, B., Nagy, Z. F., Keller-Pintér, A., Klivényi, P., Molnar, M., & Széll, M. (2025). Genetic Variants in SDC3, KCNA2, KCNK1, KCNK16, and Heat Shock Transcription Factor-1 Genes: An Exploratory Analysis Supporting the Piezo2 Channelopathy Hypothesis in Amyotrophic Lateral Sclerosis Onset. *International Journal of Molecular Sciences*. [URL](https://www.semanticscholar.org/paper/9018c898d5fa1dca8ebb475c6accea5f07b32b44)

[5] Xie, L., Zhang, M., Liu, Q., Wei, R., Sun, M.-L., Zhang, Q., Hao, L.-Y., Xue, Z.-y., Wang, Q.-h., Yang, L., Wang, H.-J., & Pan, Z. (2023). Downregulation of ciRNA‐Kat6b in dorsal spinal horn is required for neuropathic pain by regulating Kcnk1 in miRNA‐26a‐dependent manner. *CNS Neuroscience & Therapeutics*. [URL](https://www.semanticscholar.org/paper/e867fc619b70dca27deab99c4699baa78039afb8)

[6] Sun, X., Li, Y., Lan, H., Jiang, T., Wan, X., & Cheng, Y. (2022). Identification of KCNK1 as a potential prognostic biomarker and therapeutic target of breast cancer. *Pathology, Research and Practice*. [URL](https://www.semanticscholar.org/paper/d27fe0af6ba227a1a44b7d22742c8e2610867d7c)

[7] Saito, K., Moore, R., Kamino, H., & Negishi, M. (2011). The K+ Channel KCNK1: CAR‐mediated Gene Regulation of Male‐specific Induction by PB and Hepatic Hypert